These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38656186)
1. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children. Butragueño-Laiseca L; Troconiz IF; Grau S; Campillo N; Padilla B; Fernández SN; Slöcker M; Herrera L; Santiago MJ Antimicrob Agents Chemother; 2024 Apr; ():e0172923. PubMed ID: 38656186 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy. Butragueño-Laiseca L; Marco-Ariño N; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Slöcker M; Santiago MJ Clin Microbiol Infect; 2022 Sep; 28(9):1287.e9-1287.e15. PubMed ID: 35390523 [TBL] [Abstract][Full Text] [Related]
3. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis. Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374 [TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children. Cies JJ; Moore WS; Enache A; Chopra A J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201 [TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Peng Y; Cheng Z; Xie F Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753 [TBL] [Abstract][Full Text] [Related]
8. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601 [TBL] [Abstract][Full Text] [Related]
9. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations. Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811 [TBL] [Abstract][Full Text] [Related]
10. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial. Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057 [TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation. O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127 [TBL] [Abstract][Full Text] [Related]
13. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194 [TBL] [Abstract][Full Text] [Related]
15. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients. Gan Y; Meng X; Lei N; Yu H; Zeng Q; Huang Q Infect Drug Resist; 2023; 16():3989-3997. PubMed ID: 37366501 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of meropenem in critically ill children with different renal functions. Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149 [TBL] [Abstract][Full Text] [Related]
17. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy. Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170 [TBL] [Abstract][Full Text] [Related]
18. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study. Areskog Lejbman I; Torisson G; Resman F; Sjövall F Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection. Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867 [TBL] [Abstract][Full Text] [Related]
20. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study. Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]